Metacox 15 mg ad us. vet.

Hauptinformation

  • Handelsname:
  • Metacox® 15 mg ad us. vet., orale Suspension
  • Darreichungsform:
  • orale Suspension
  • Verwenden für:
  • Tiere
  • Art der Medizin:
  • allopathic Droge

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Metacox® 15 mg ad us. vet., orale Suspension
    Schweiz
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiegruppe:
  • Nichtsteroidales Antiphlogistikum für Pferde

Weitere Informationen

Status

  • Quelle:
  • Institut für Veterinärpharmakologie
  • Zulassungsnummer:
  • 65142
  • Letzte Änderung:
  • 02-09-2017

Packungsbeilage: zusammensetzung, kinische angaben, nebenwirkungen, wechselwirkungen, dosierung, schwangerschaft, stillzeit

Metacox

15 mg ad us. vet., orale Suspension

Dr. E. Graeub AG

Nichtsteroidales Antiphlogistikum für Pferde

ATCvet: QM01AC06

Zusammensetzung

1 ml Suspension enthält:

Meloxicam 15 mg

Aromatica: Saccharinum natricum et alia, Conserv.: Natrii benzoas E211

Excip. ad susp.

Fachinformationen Wirkstoffe (CliniPharm)

Meloxicam

Eigenschaften / Wirkungen

Meloxicam ist ein nichtsteroidales Antiphlogistikum (NSAID) der Oxicam-Gruppe, das die

Prostaglandinsynthese hemmt und antiinflammatorisch, analgetisch, antiexsudativ und

antipyretisch wirkt. Es reduziert die Leukozyteninfiltration in das entzündete Gewebe.

Ausserdem besteht eine schwache Hemmung der kollageninduzierten

Thrombozytenaggregation. Meloxicam verfügt ebenfalls über antiendotoxische

Eigenschaften. Es konnte gezeigt werden, dass die Thromboxan B2 Produktion bei

Kälbern und Schweinen nach intravenöser E. coli-Endotoxin Verabreichung durch

Meloxicam gehemmt wird.

Pharmakokinetik

Absorption:

Wird das Tierarzneimittel entsprechend der Dosierungsanleitung verabreicht, beträgt die

orale Bioverfügbarkeit ungefähr 98%. Maximale Plasmakonzen-trationen werden nach

ungefähr 2 - 3 Stunden erreicht. Der Kumulationsfaktor von 1.08 weist darauf hin, dass

sich Meloxicam bei 1 × täglicher Verabreichung nicht anreichert.

Verteilung:

Meloxicam ist zu ungefähr 98% an Plasmaproteine gebunden. Das Verteilungsvolumen

beträgt 0.12 l/kg.

Metabolismus:

Der Metabolismus bei Ratten, Minipigs, Menschen, Rindern und Schweinen ist qualitativ

ähnlich, unterscheidet sich jedoch quantitativ. Die in allen Spezies gefundenen

Hauptmetaboliten sind 5-Hydroxy- und 5-Carboxy-Metaboliten sowie Oxalyl-Metaboliten.

Der Metabolismus bei Pferden wurde nicht untersucht. Alle Hauptmetaboliten haben sich

als pharmakologisch inaktiv erwiesen.

Elimination:

Meloxicam wird mit einer Eliminationshalbwertszeit von 7.7 Stunden ausgeschieden.

Indikationen

Linderung von Entzündungen und Schmerzen bei akuten und chronischen Erkrankungen

des Bewegungsapparates.

Metacox orale Suspension ist einmal täglich in einer Dosis von 0.6 mg Meloxicam pro kg

Körpergewicht (entspr. 1 ml pro 25 kg Körpergewicht) mit dem Futter vermischt oder direkt

in das Maul zu verabreichen (während maximal 14 Tagen).

Bei Verabreichung mit dem Futter sollte das Präparat mit wenig Futter vermischt vor der

eigentlichen Fütterung verabreicht werden.

Die Suspension sollte mit Hilfe der beiliegenden Metacox Dosierspritze verabreicht

werden. Die Spritze passt auf die Flasche und weist eine Skala in kg Körpergewicht

Graduierungsschritten auf.

Vor Gebrauch gut schütteln. Verunreinigungen während der Entnahme vermeiden.

Im Falle einer Überdosierung soll eine symptomatische Behandlung eingeleitet werden.

Anwendungseinschränkungen

Kontraindikationen

Nicht anwenden bei trächtigen oder säugenden Stuten.

Nicht anwenden bei Pferden mit gastrointestinalen Störungen wie Ulzerationen oder

Hämorrhagien.

Nicht anwenden bei Funktionsstörungen von Leber, Herz oder Nieren. Weitere

Gegenanzeigen sind Blutgerinnungsstörungen.

Nicht anwenden bei bekannter Überempfindlichkeit gegenüber dem Wirkstoff oder einem

der sonstigen Bestandteile.

Nicht anwenden bei Pferden, die jünger als 6 Wochen sind.

Vorsichtsmassnahmen

Falls Nebenwirkungen auftreten, sollte die Behandlung abgebrochen und der Rat eines

Tierarztes eingeholt werden.

Nicht anwenden bei dehydrierten, hypovolämischen oder hypotonischen Tieren, da hier

ein potentielles Risiko einer Nierentoxizität besteht.

Laborstudien am Rind haben keinen Hinweis auf teratogene, foetotoxische oder

maternotoxische Wirkungen geliefert. Es wurden jedoch keine Daten für das Pferd

erhoben. Deshalb wird die Anwendung bei dieser Spezies während Trächtigkeit und

Säugezeit / Laktation nicht empfohlen.

Unerwünschte Wirkungen

VetVigilance: Pharmacovigilance-Meldung erstatten

In Einzelfällen wurden während der klinischen Studien die für NSAIDs typischen

Nebenwirkungen (leichte Urtikaria, Diarrhoe) beobachtet. Die Symptome waren nach

Absetzen der Therapie reversibel.

In sehr seltenen Fällen wurde über Appetitverlust, Lethargie, abdominalen Schmerz und

Colitis berichtet.

In sehr seltenen Fällen kann es zu anaphylaktoiden Reaktionen kommen, die

schwerwiegend sein können (auch lebensbedrohend). Diese sollten symptomatisch

behandelt werden.

Essbare Gewebe: 3 Tage

Nicht bei Stuten anwenden, deren Milch für den menschlichen Verzehr vorgesehen ist.

Wechselwirkungen

Nicht zusammen mit Glukokortikoiden, anderen nichtsteroidalen Antiphlogistika oder

Antikoagulantien verabreichen.

Sonstige Hinweise

Lagerungshinweise

Bei Raumtemperatur (15 - 25°C) aufbewahren. Nach Verabreichen des Medikamentes die

Flasche mit dem Deckel wieder verschliessen und die Dosierspritze mit warmem Wasser

ausspülen und trocknen lassen. Medikament ausser Reichweite von Kindern

aufbewahren. Das Präparat darf nur bis zu dem auf der Packung mit "EXP." bezeichneten

Datum verwendet werden. Aufbrauchfrist nach 1. Entnahme: 3 Monate

Anwenderhinweise

Personen mit bekannter Überempfindlichkeit gegenüber NSAIDs sollten den direkten

Kontakt mit dem Tierarzneimittel vermeiden. Bei versehentlicher Einnahme ist

unverzüglich ein Arzt aufzusuchen (Packungsbeilage mitnehmen!).

Packungen

Flaschen zu 100 ml und 250 ml mit Dosierspritze

Abgabekategorie: B

Swissmedic Nr. 65'142

Informationsstand: 02/2014

Dieser Text ist behördlich genehmigt.

21-3-2019

Modification of the existing maximum residue levels for pyridaben in tomatoes and aubergines

Modification of the existing maximum residue levels for pyridaben in tomatoes and aubergines

Published on: Wed, 20 Mar 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Nissan Chemical Europe S.A.S. submitted a request to the competent national authority in the Netherlands to modify the existing maximum residue levels (MRLs) for the active substance pyridaben in tomatoes and aubergines. An MRL proposal of 0.15 mg/kg was derived for tomatoes and aubergines which reflects the intended use of the plant protection product containing pyridaben. Adequate analytical metho...

Europe - EFSA - European Food Safety Authority EFSA Journal

21-3-2019

Modification of the existing maximum residue level for cyprodinil in Florence fennel

Modification of the existing maximum residue level for cyprodinil in Florence fennel

Published on: Wed, 20 Mar 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the FPS Health, Food chain safety and Environment of Belgium, submitted an application to modify the existing maximum residue level (MRL) for the active substance cyprodinil in Florence fennel to accommodate the intended use in the northern Europe. The submitted data were found sufficient to derive an MRL proposal of 4 mg/kg for cyprodinil in Florence fennel. Adequate analytical methods for enforcement are availa...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-3-2019

Legrand recalls 15-Amp 125-Volt White Indoor Duplex Wall Outlet

Legrand recalls 15-Amp 125-Volt White Indoor Duplex Wall Outlet

The affected product has not been approved to the Canadian standards for electrical products and it is unknown if the product is in compliance with the applicable safety standard.

Health Canada

20-3-2019

Safety and efficacy of eight compounds belonging to different chemical groups when used as flavourings for cats and dogs

Safety and efficacy of eight compounds belonging to different chemical groups when used as flavourings for cats and dogs

Published on: Tue, 19 Mar 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of 23 compounds belonging to different chemical groups. This opinion concerns eight out of the 23 compounds, which are currently authorised for use as flavours in food. The Panel concludes that the eight additives are safe for cats and dogs at the proposed use level: phenyl...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-3-2019

Safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters) when used as flavourings for all animal species and categories

Safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters) when used as flavourings for all animal species and categories

Published on: Tue, 19 Mar 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters). They are all currently authorised as flavours in food. The FEEDAP Panel was unable to perform the assessment of non‐2(c...

Europe - EFSA - European Food Safety Authority EFSA Journal

18-3-2019

Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter

Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter

Mylan Institutional LLC is conducting a voluntary nationwide recall of two lots (see table below) of Levoleucovorin Injection, 250 mg/25 mL to the consumer/user level. The lots were manufactured by Alidac Pharmaceuticals Limited and distributed by Mylan Institutional LLC.

FDA - U.S. Food and Drug Administration

16-3-2019

Efficacy of sodium formate as a technological feed additive (hygiene condition enhancer) for all animal species

Efficacy of sodium formate as a technological feed additive (hygiene condition enhancer) for all animal species

Published on: Fri, 15 Mar 2019 In 2015, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) issued an opinion on the safety and efficacy of formic acid, ammonium formate and sodium formate as feed hygiene agents for all animal species. In this opinion, two forms of the additive sodium formate, a solid form (specified to contain ≥ 98% sodium formate (w/w)) and a liquid form (specified to contain a minimum of 15% sodium formate, a maximum of 75% free formic acid and a maxim...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-3-2019

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 50mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical Ingredient

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 50mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical Ingredient

Legacy Pharmaceutical Packaging, LLC is recalling 3 repackaged lots of Losartan Tablets USP 50mg to the consumer level. This recall was prompted due to Torrent Pharmaceuticals LTD issuing a Voluntary Nationwide Recall of Losartan Tablets, USP, due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, (API manufacturer).

FDA - U.S. Food and Drug Administration

16-3-2019

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmace

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmace

Earth City, MO, Legacy Pharmaceutical Packaging, LLC is recalling 40 repackaged lots of Losartan Tablets USP 25mg, 50mg, and 100mg to the consumer level. This recall was prompted due to Camber Pharmaceuticals, Inc. issuing a Voluntary Nationwide Recall of Losartan Tablets, USP, due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, (API manufacturer).

FDA - U.S. Food and Drug Administration

15-3-2019

Modification of the existing maximum residue level for fluopyram in broccoli

Modification of the existing maximum residue level for fluopyram in broccoli

Published on: Thu, 14 Mar 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Bayer Hellas AG submitted a request to the competent national authority in Greece to modify the existing maximum residue level (MRL) for the active substance fluopyram in broccoli. The data submitted in support of the request were found to be sufficient to derive MRL proposals for broccoli. Adequate analytical methods for enforcement are available to control the residues of fluopyram on the commodit...

Europe - EFSA - European Food Safety Authority EFSA Journal

14-3-2019

Safety of annatto E and the exposure to the annatto colouring principles bixin and norbixin (E 160b) when used as a food additive

Safety of annatto E and the exposure to the annatto colouring principles bixin and norbixin (E 160b) when used as a food additive

Published on: Wed, 13 Mar 2019 The Scientific Panel on Food Additives and Flavouring (FAF) provides a scientific opinion on the safety evaluation of annatto E and an exposure assessment of the annatto colouring principles bixin and norbixin (E 160b) when used as a food additive, taking into account new proposed uses and use levels. In 2016, the EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) adopted a scientific opinion on the safety of annatto extracts (E 160b) as a food additive....

Europe - EFSA - European Food Safety Authority EFSA Journal

14-3-2019

Safety evaluation of the food enzyme β‐glucanase, xylanase and cellulase from Mycothermus thermophiloides (strain NZYM‐ST)

Safety evaluation of the food enzyme β‐glucanase, xylanase and cellulase from Mycothermus thermophiloides (strain NZYM‐ST)

Published on: Fri, 08 Mar 2019 The food enzyme has three declared activities (endo‐1,3(4)‐β‐glucanase EC 3.2.1.6, endo‐1,4‐β‐xylanase EC 3.2.1.8 and cellulase (endo‐1,4‐β‐d‐glucanase EC 3.2.1.4)) and is produced with a non‐genetically modified Mycothermus thermophiloides strain by Novozymes A/S. It is intended to be used in baking and brewing processes. For the two intended uses, based on the maximum use levels recommended and individual data from the EFSA Comprehensive European Food Database, dietary e...

Europe - EFSA - European Food Safety Authority EFSA Journal

13-3-2019

Safety evaluation of the food enzyme triacylglycerol lipase from Aspergillus niger (strain LFS)

Safety evaluation of the food enzyme triacylglycerol lipase from Aspergillus niger (strain LFS)

Published on: Tue, 12 Mar 2019 The food enzyme triacylglycerol lipase (triacylglycerol acylhydrolase, EC 3.1.1.3) is produced with a genetically modified Aspergillus niger strain LFS by DSM Food Specialties B.V.. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The triacylglycerol lipase food enzyme is intended to be used in baking processes. Based on the maximum use levels, dietary exposure to the fo...

Europe - EFSA - European Food Safety Authority EFSA Journal

13-3-2019

Safety evaluation of the food enzyme glucose oxidase from Aspergillus niger (strain ZGL)

Safety evaluation of the food enzyme glucose oxidase from Aspergillus niger (strain ZGL)

Published on: Tue, 12 Mar 2019 The food enzyme glucose oxidase (β‐d‐glucose:oxygen 1‐oxidoreductase; EC 1.1.3.4) is produced with a genetically modified Aspergillus niger strain ZGL by DSM Food Specialties B.V.. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The glucose oxidase is intended to be used in baking processes. Based on the maximum use levels, dietary exposure to the food enzyme‐total orga...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-3-2019


Agenda - PRAC draft agenda of meeting 12-15 March 2019

Agenda - PRAC draft agenda of meeting 12-15 March 2019

Agenda - PRAC draft agenda of meeting 12-15 March 2019

Europe - EMA - European Medicines Agency

22-3-2019

ACSS public statement, 14-15 May 2018

ACSS public statement, 14-15 May 2018

Public statement for the Generic Medicines Working Group face-to-face meeting in Switzerland, May 2018

Therapeutic Goods Administration - Australia

22-3-2019

Flecagamma 100 mg Tabletten

Rote - Liste

21-3-2019

Riamet 20/120 mg Tabletten

Rote - Liste

21-3-2019

Ritalin 10 mg Tabletten

Rote - Liste

21-3-2019

Tramal® Zäpfchen, 100 mg

Rote - Liste

20-3-2019

Methizol® SD 5 mg/- 20 mg

Rote - Liste

20-3-2019

Diacomit 250 mg Hartkapseln

Rote - Liste

20-3-2019

Diacomit 250 mg Pulver

Rote - Liste

20-3-2019

Diacomit 500 mg Pulver

Rote - Liste

20-3-2019

Diacomit 500 mg Hartkapseln

Rote - Liste

20-3-2019

Dopamin Fresenius 250/500 mg/50 ml

Rote - Liste

20-3-2019

Dopamin Fresenius 50/200 mg/5 ml

Rote - Liste

19-3-2019

Nevirapin Mylan 200 mg Tabletten

Rote - Liste

19-3-2019

Tramal® Kapseln, 50 mg, Hartkapseln

Rote - Liste

18-3-2019

EU/3/15/1587 (Diamond ROC EOOD)

EU/3/15/1587 (Diamond ROC EOOD)

EU/3/15/1587 (Active substance: Combretastatin A1 diphosphate) - Transfer of orphan designation - Commission Decision (2019)2149 of Mon, 18 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003811

Europe -DG Health and Food Safety

18-3-2019

EU/3/15/1584 (Diamond ROC EOOD)

EU/3/15/1584 (Diamond ROC EOOD)

EU/3/15/1584 (Active substance: Variant of recombinant human fibroblast growth factor 19) - Transfer of orphan designation - Commission Decision (2019)2148 of Mon, 18 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003801

Europe -DG Health and Food Safety

15-3-2019


Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 12-15 March 2019

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 12-15 March 2019

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 12-15 March 2019

Europe - EMA - European Medicines Agency

15-3-2019

Ongentys (Bial - Portela and Ca, SA)

Ongentys (Bial - Portela and Ca, SA)

Ongentys (Active substance: opicapone) - Centralised - Yearly update - Commission Decision (2019)2113 of Fri, 15 Mar 2019

Europe -DG Health and Food Safety

15-3-2019

Intrarosa (Endoceutics S.A.)

Intrarosa (Endoceutics S.A.)

Intrarosa (Active substance: prasterone) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2063 of Fri, 15 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/004138/T/0005

Europe -DG Health and Food Safety

15-3-2019

NovoMix (Novo Nordisk A/S)

NovoMix (Novo Nordisk A/S)

NovoMix (Active substance: Insulin aspart) - Centralised - 2-Monthly update - Commission Decision (2019)2114 of Fri, 15 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/000308/II/0095

Europe -DG Health and Food Safety

15-3-2019

Zoledronic acid Accord (Accord Healthcare S.L.U.)

Zoledronic acid Accord (Accord Healthcare S.L.U.)

Zoledronic acid Accord (Active substance: zoledronic acid) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2071 of Fri, 15 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/002667/T/0007

Europe -DG Health and Food Safety

15-3-2019

EU/3/14/1249 (Akcea Therapeutics Ireland Limited)

EU/3/14/1249 (Akcea Therapeutics Ireland Limited)

EU/3/14/1249 (Active substance: Phosphorothioate oligonucleotide targeted to apolipoprotein C-III) - Transfer of orphan designation - Commission Decision (2019)2104 of Fri, 15 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004954

Europe -DG Health and Food Safety

15-3-2019

EU/3/19/2139 (Clinical Network Services (NL) B.V.)

EU/3/19/2139 (Clinical Network Services (NL) B.V.)

EU/3/19/2139 (Active substance: Autologous adult live cultured osteoblasts) - Transfer of orphan designation - Commission Decision (2019)2105 of Fri, 15 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004280

Europe -DG Health and Food Safety

15-3-2019

EU/3/06/349 (Vectura Ireland Limited)

EU/3/06/349 (Vectura Ireland Limited)

EU/3/06/349 (Active substance: Apomorphine hydrochloride (inhalation use)) - Transfer of orphan designation - Commission Decision (2019)2115 of Fri, 15 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004495

Europe -DG Health and Food Safety

15-3-2019

EU/3/15/1597 (Otsuka Pharmaceutical Netherlands B.V.)

EU/3/15/1597 (Otsuka Pharmaceutical Netherlands B.V.)

EU/3/15/1597 (Active substance: Sodium (2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1(2H)-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl ((2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9(6H)-yl)-3-hydroxytetrahydrofuran-2-yl)methyl phosphate) - Transfer of orphan designation - Commission Decision (2019)2107 of Fri, 15 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004914

Europe -DG Health and Food Safety

15-3-2019

EU/3/11/936 (BPL Bioproducts Laboratory GmbH)

EU/3/11/936 (BPL Bioproducts Laboratory GmbH)

EU/3/11/936 (Active substance: Human haptoglobin) - Transfer of orphan designation - Commission Decision (2019)2106 of Fri, 15 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004485

Europe -DG Health and Food Safety

15-3-2019

EU/3/16/1800 (Boyd Consultants Limited)

EU/3/16/1800 (Boyd Consultants Limited)

EU/3/16/1800 (Active substance: Dantrolene sodium) - Transfer of orphan designation - Commission Decision (2019)2111 of Fri, 15 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005192

Europe -DG Health and Food Safety

15-3-2019

EU/3/16/1629 (Boyd Consultants Limited)

EU/3/16/1629 (Boyd Consultants Limited)

EU/3/16/1629 (Active substance: Exenatide) - Transfer of orphan designation - Commission Decision (2019)2110 of Fri, 15 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005191

Europe -DG Health and Food Safety

15-3-2019

EU/3/14/1396 (Boyd Consultants Limited)

EU/3/14/1396 (Boyd Consultants Limited)

EU/3/14/1396 (Active substance: Adenovirus serotype 5 containing partial E1A deletion and an integrin-binding domain) - Transfer of orphan designation - Commission Decision (2019)2109 of Fri, 15 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005074

Europe -DG Health and Food Safety

15-3-2019

EU/3/11/895 (Boyd Consultants Limited)

EU/3/11/895 (Boyd Consultants Limited)

EU/3/11/895 (Active substance: Hydroxy-propyl-beta-cyclodextrin) - Transfer of orphan designation - Commission Decision (2019)2108 of Fri, 15 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000005321

Europe -DG Health and Food Safety

15-3-2019

Lamisil 250 mg Tabletten

Rote - Liste

15-3-2019

Vesikur 5 mg/10 mg Filmtabletten

Rote - Liste

15-3-2019

Irinotecan Kabi 20 mg/ml

Rote - Liste

15-3-2019

lbuSinex 200 mg/30 mg Filmtabletten

Rote - Liste

14-3-2019


Orphan designation: Treprostinil diethanolamine, Treatment of systemic sclerosis, 15/05/2009, Positive

Orphan designation: Treprostinil diethanolamine, Treatment of systemic sclerosis, 15/05/2009, Positive

Orphan designation: Treprostinil diethanolamine, Treatment of systemic sclerosis, 15/05/2009, Positive

Europe - EMA - European Medicines Agency

13-3-2019

Varuby (TESARO Bio Netherlands B.V.)

Varuby (TESARO Bio Netherlands B.V.)

Varuby (Active substance: rolapitant) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2068 of Wed, 13 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4196/T/15

Europe -DG Health and Food Safety

13-3-2019

Updated GMP licence application e-forms

Updated GMP licence application e-forms

GMP Licence submission e-forms will be updated on the TBS portal from 15 March 2019 to support the revised fees and charges model

Therapeutic Goods Administration - Australia